Literature DB >> 19741545

Prevalence and distribution of high-risk human papillomavirus in Greece.

Theodoros Agorastos1, Alexandros F Lambropoulos, Alexandros Sotiriadis, Themistoklis Mikos, Eleonora Togaridou, Christos J Emmanouilides.   

Abstract

As knowledge of regional human papillomavirus (HPV) type distribution is essential for the optimization of prevention strategies, this study was carried out to explore the prevalence and type distribution of high-risk HPV in a screening population across Greece. Cervical samples were collected by local physicians and nurses in hospitals and health centers across the country from 4139 women attending for cervical cancer screening. High-risk HPV-DNA was detected by using Hybrid Capture-2 (HC2) and positive samples with adequate cellular content were further typed by restriction fragment length polymorphism-polymerase chain reaction. Almost six percent (5.9%) of women tested positive in HC2. The most common type was HPV16 (1.4% in the whole sample and 32.4% of the typed samples), followed by HPV53 (0.6 and 14.0%, respectively), HPV31 (0.6 and 12.9%, respectively), HPV35 (0.5 and 12.3%, respectively), HPV51 (0.4 and 7.8%, respectively), HPV18 (0.3 and 7.3%, respectively) and 22 more types. Almost 15% of the typed samples showed a coinfection with two HPV types and 2.1% with three types. There was a bimodal distribution by age, with the highest peak in women 20-29 years old and a lower peak in women 50-59 years old. Apart from the types originally included in HC2 cocktail, PCR analysis identified 15 more types (HPV6, HPV11, HPV34, HPV37, HPV38, HPV42, HPV53, HPV54, HPV55, HPV61, HPV62, HPV66, HPV73, HPV82, HPV83). Eleven percent of HC2-positive results arose from single-type infections with HPV53 (10%) and HPV66 (1%), which are potentially high-risk types. In conclusion, HPV16 is the most common type in the largest Greek screening sample used to date and, together with its related types, accounts for more than half of high-risk HPV infections. Approximately 10% of positive HC2 results arise from HPV53, which is not normally detected by the test, but may be clinically significant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19741545     DOI: 10.1097/CEJ.0b013e32832abd5e

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  5 in total

Review 1.  Human papillomavirus infection by anatomical site among Greek men and women: a systematic review.

Authors:  Savas Tsikis; Lea Hoefer; Angella Charnot-Katsikas; John A Schneider
Journal:  Eur J Cancer Prev       Date:  2016-11       Impact factor: 2.497

2.  Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.

Authors:  Theodoros Agorastos; Kimon Chatzistamatiou; Taxiarchis Katsamagkas; George Koliopoulos; Alexandros Daponte; Theocharis Constantinidis; Theodoros C Constantinidis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  A cross sectional study of HPV type prevalence according to age and cytology.

Authors:  Elena Argyri; Stefanos Papaspyridakos; Elpida Tsimplaki; Lina Michala; Evangelia Myriokefalitaki; Issidora Papassideri; Dimitra Daskalopoulou; Ioanna Tsiaoussi; George Magiakos; Efstathia Panotopoulou
Journal:  BMC Infect Dis       Date:  2013-01-30       Impact factor: 3.090

4.  Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland.

Authors:  M K Leinonen; A Anttila; N Malila; J Dillner; O Forslund; P Nieminen
Journal:  Br J Cancer       Date:  2013-10-17       Impact factor: 7.640

5.  Knowledge, beliefs and communication preferences with regards to the HPV vaccine; the perspective of unvaccinated Greek adolescent girls, young women, and mothers of vaccine-eligible girls.

Authors:  Christina Karamanidou; Κostas Dimopoulos
Journal:  Health Psychol Behav Med       Date:  2018-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.